Company news

Helix BioPharma Corp. news in 2026

Helix BioPharma Corp.'s news releases, calls and decks from 2026, newest first.

View company

YE 2026 MD&A | Management’s discussion and analysis of financial condition and results of operations

October 30, 2026

Helix BioPharma: Press release | Helix BioPharma Corp. Announces Fiscal 2026 Year-End results

October 30, 2026

2026 AIF | Annual Information Form

October 30, 2026

Helix BioPharma Corp. Announces Fiscal 2026 Year-End Results

October 29, 2026

Helix BioPharma Strengthens Biotech Leadership and Corporate Governance through planned Board Changes

September 28, 2026

Helix BioPharma Strengthens Biotech Leadership and Corporate Governance Through Planned Board Changes

September 28, 2026

Helix BioPharma Corp. Appoints Markus Loeffler, MD, MBA, as Chief Medical Officer to Support Next Phase of Clinical Development

August 17, 2026

Helix Biopharma Corp. Announces Board Composition Changes

August 14, 2026

Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development

June 30, 2026

Q3 2026 MD&A | Management’s discussion and analysis of financial condition and results of operations

June 15, 2026

Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026

June 12, 2026

Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures

June 3, 2026

Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options

May 22, 2026

Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy

May 13, 2026

Q2 2026 MD&A | Management’s discussion and analysis of financial condition and results of operations

March 17, 2026

Helix BioPharma: Financial statements, Second Quarter 2026

March 17, 2026

Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026

March 16, 2026

Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London

February 24, 2026

Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases

February 5, 2026

Helix Biopharma Corp. Extends LEUMUNA Option With metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases

February 5, 2026

Helix BioPharma Corp. Announces Voting Results from its Annual General and Special Meeting

January 30, 2026

Helix BioPharma Corp. Announces Voting Results From Its Annual General and Special Meeting

January 30, 2026

Decks in 2026